Clinical TrialsThe BEACON trial update reinforces clinical differentiation of BEAM-101 in sickle cell disease, with patients achieving a favorable hemoglobin profile and no vaso-occlusive crises reported post-treatment.
Regulatory ProgressBeam anticipates that data from 30 to 45 patients from the BEACON trial may be sufficient to support a biologics license application for BEAM-101, viewing it as a potentially best-in-class option for patients with severe sickle cell disease.
Safety And EfficacyBeam's data continue to demonstrate best-in-class efficacy and safety as compared to peers.